Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aethlon Medical, Inc. stock logo
AEMD
Aethlon Medical
$1.51
-0.1%
$1.65
$1.35
$5.00
$3.96M1.888,533 shs382 shs
Arrayit Co. stock logo
ARYC
Arrayit
$0.00
$0.00
$0.00
N/A-1.2N/AN/A
Bionano Genomics, Inc. stock logo
BNGO
Bionano Genomics
$0.78
-2.2%
$1.08
$0.71
$8.20
$42.51M2.331.64 million shs418,352 shs
HTG Molecular Diagnostics, Inc. stock logo
HTGM
HTG Molecular Diagnostics
$6.00
$3.50
$7.95
N/A0.99294,806 shs773,040 shs
Precipio, Inc. stock logo
PRPO
Precipio
$6.15
-2.8%
$6.41
$4.75
$14.80
$8.79M1.614,197 shs3,618 shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aethlon Medical, Inc. stock logo
AEMD
Aethlon Medical
+5.73%+5.00%-11.58%-24.03%-71.37%
Arrayit Co. stock logo
ARYC
Arrayit
0.00%0.00%0.00%0.00%0.00%
Bionano Genomics, Inc. stock logo
BNGO
Bionano Genomics
+4.44%-7.14%-23.62%-35.94%-89.80%
HTG Molecular Diagnostics, Inc. stock logo
HTGM
HTG Molecular Diagnostics
0.00%0.00%0.00%0.00%-84.36%
Precipio, Inc. stock logo
PRPO
Precipio
-2.84%-8.62%+2.16%-5.09%-50.40%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aethlon Medical, Inc. stock logo
AEMD
Aethlon Medical
1.3097 of 5 stars
3.53.00.00.01.10.00.6
Arrayit Co. stock logo
ARYC
Arrayit
N/AN/AN/AN/AN/AN/AN/AN/A
Bionano Genomics, Inc. stock logo
BNGO
Bionano Genomics
2.0778 of 5 stars
3.33.00.00.02.60.01.3
HTG Molecular Diagnostics, Inc. stock logo
HTGM
HTG Molecular Diagnostics
N/AN/AN/AN/AN/AN/AN/AN/A
Precipio, Inc. stock logo
PRPO
Precipio
0.3353 of 5 stars
2.03.00.00.00.00.80.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aethlon Medical, Inc. stock logo
AEMD
Aethlon Medical
3.00
Buy$10.00562.25% Upside
Arrayit Co. stock logo
ARYC
Arrayit
N/AN/AN/AN/A
Bionano Genomics, Inc. stock logo
BNGO
Bionano Genomics
2.67
Moderate Buy$21.332,644.90% Upside
HTG Molecular Diagnostics, Inc. stock logo
HTGM
HTG Molecular Diagnostics
N/AN/AN/AN/A
Precipio, Inc. stock logo
PRPO
Precipio
N/AN/A$40.00550.41% Upside

Current Analyst Ratings

Latest BNGO, AEMD, PRPO, ARYC, and HTGM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/7/2024
Bionano Genomics, Inc. stock logo
BNGO
Bionano Genomics
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Outperform ➝ Sector Outperform$7.00 ➝ $6.00
3/4/2024
Aethlon Medical, Inc. stock logo
AEMD
Aethlon Medical
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$23.00 ➝ $10.00
(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aethlon Medical, Inc. stock logo
AEMD
Aethlon Medical
$570K6.94N/AN/A$6.56 per share0.23
Arrayit Co. stock logo
ARYC
Arrayit
N/AN/AN/AN/AN/AN/A
Bionano Genomics, Inc. stock logo
BNGO
Bionano Genomics
$36.12M1.18N/AN/A$2.10 per share0.37
HTG Molecular Diagnostics, Inc. stock logo
HTGM
HTG Molecular Diagnostics
$6.37M0.00N/AN/A$2.44 per share0.00
Precipio, Inc. stock logo
PRPO
Precipio
$15.20M0.58N/AN/A$10.16 per share0.61

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aethlon Medical, Inc. stock logo
AEMD
Aethlon Medical
-$12.03M-$4.99N/AN/AN/AN/A-106.28%-86.60%6/26/2024 (Estimated)
Arrayit Co. stock logo
ARYC
Arrayit
N/AN/A0.00N/AN/AN/AN/AN/AN/A
Bionano Genomics, Inc. stock logo
BNGO
Bionano Genomics
-$232.49M-$6.62N/AN/AN/A-643.74%-103.68%-71.45%5/14/2024 (Estimated)
HTG Molecular Diagnostics, Inc. stock logo
HTGM
HTG Molecular Diagnostics
-$21.59MN/A0.00N/AN/A-324.25%45.52%8.93%N/A
Precipio, Inc. stock logo
PRPO
Precipio
-$5.85M-$4.56N/AN/A-38.51%-51.75%-37.93%5/10/2024 (Estimated)

Latest BNGO, AEMD, PRPO, ARYC, and HTGM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/5/2024Q4 2023
Bionano Genomics, Inc. stock logo
BNGO
Bionano Genomics
N/A-$0.96-$0.96-$0.96N/A$10.72 million
2/14/2024Q3 2024
Aethlon Medical, Inc. stock logo
AEMD
Aethlon Medical
-$1.23-$1.37-$0.14-$1.37N/AN/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aethlon Medical, Inc. stock logo
AEMD
Aethlon Medical
N/AN/AN/AN/AN/A
Arrayit Co. stock logo
ARYC
Arrayit
N/AN/AN/AN/AN/A
Bionano Genomics, Inc. stock logo
BNGO
Bionano Genomics
N/AN/AN/AN/AN/A
HTG Molecular Diagnostics, Inc. stock logo
HTGM
HTG Molecular Diagnostics
N/AN/AN/AN/AN/A
Precipio, Inc. stock logo
PRPO
Precipio
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aethlon Medical, Inc. stock logo
AEMD
Aethlon Medical
N/A
3.93
3.93
Arrayit Co. stock logo
ARYC
Arrayit
N/AN/AN/A
Bionano Genomics, Inc. stock logo
BNGO
Bionano Genomics
0.04
1.40
1.17
HTG Molecular Diagnostics, Inc. stock logo
HTGM
HTG Molecular Diagnostics
N/A
1.40
1.30
Precipio, Inc. stock logo
PRPO
Precipio
0.01
1.17
1.05

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Aethlon Medical, Inc. stock logo
AEMD
Aethlon Medical
1.99%
Arrayit Co. stock logo
ARYC
Arrayit
N/A
Bionano Genomics, Inc. stock logo
BNGO
Bionano Genomics
11.35%
HTG Molecular Diagnostics, Inc. stock logo
HTGM
HTG Molecular Diagnostics
19.27%
Precipio, Inc. stock logo
PRPO
Precipio
10.45%

Insider Ownership

CompanyInsider Ownership
Aethlon Medical, Inc. stock logo
AEMD
Aethlon Medical
4.00%
Arrayit Co. stock logo
ARYC
Arrayit
58.00%
Bionano Genomics, Inc. stock logo
BNGO
Bionano Genomics
2.44%
HTG Molecular Diagnostics, Inc. stock logo
HTGM
HTG Molecular Diagnostics
2.60%
Precipio, Inc. stock logo
PRPO
Precipio
10.60%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Aethlon Medical, Inc. stock logo
AEMD
Aethlon Medical
152.62 million2.52 millionOptionable
Arrayit Co. stock logo
ARYC
Arrayit
7N/AN/ANot Optionable
Bionano Genomics, Inc. stock logo
BNGO
Bionano Genomics
34454.69 million53.36 millionOptionable
HTG Molecular Diagnostics, Inc. stock logo
HTGM
HTG Molecular Diagnostics
842.21 million2.16 millionOptionable
Precipio, Inc. stock logo
PRPO
Precipio
511.43 million1.28 millionNo Data

BNGO, AEMD, PRPO, ARYC, and HTGM Headlines

SourceHeadline
Precipio (NASDAQ:PRPO) Stock Price Crosses Below 200-Day Moving Average of $6.64Precipio (NASDAQ:PRPO) Stock Price Crosses Below 200-Day Moving Average of $6.64
americanbankingnews.com - April 24 at 3:46 AM
Precipio, Inc. (PRPO) Latest Stock News & Headlines - Yahoo FinancePrecipio, Inc. (PRPO) Latest Stock News & Headlines - Yahoo Finance
finance.yahoo.com - April 20 at 10:44 PM
Precipio Inc PRPOPrecipio Inc PRPO
morningstar.com - April 19 at 4:06 PM
Precipio (NASDAQ:PRPO) Stock Price Crosses Below 200-Day Moving Average of $6.62Precipio (NASDAQ:PRPO) Stock Price Crosses Below 200-Day Moving Average of $6.62
americanbankingnews.com - April 16 at 3:36 AM
Precipio Announces Year end 2023 Shareholder Update CallPrecipio Announces Year end 2023 Shareholder Update Call
globenewswire.com - March 25 at 5:00 PM
Precipio, Inc. (PRPO)Precipio, Inc. (PRPO)
ca.finance.yahoo.com - March 12 at 9:50 AM
Precipio Stock (NASDAQ:PRPO), Analyst Ratings, Price Targets, PredictionsPrecipio Stock (NASDAQ:PRPO), Analyst Ratings, Price Targets, Predictions
benzinga.com - February 23 at 5:33 AM
Precipio to Report $15.2M for FY-2023 (unaudited) Revenues, an increase of 60% YoYPrecipio to Report $15.2M for FY-2023 (unaudited) Revenues, an increase of 60% YoY
finance.yahoo.com - February 13 at 5:30 PM
Precipio, Inc.: Precipio and Cardinal Health Sign Distribution Agreement for its HemeScreen Portfolio of Molecular assays for CancerPrecipio, Inc.: Precipio and Cardinal Health Sign Distribution Agreement for its HemeScreen Portfolio of Molecular assays for Cancer
finanznachrichten.de - February 6 at 4:00 PM
Precipio’s Q4 cash burn from operations drops below $100K for full quarterPrecipio’s Q4 cash burn from operations drops below $100K for full quarter
msn.com - January 23 at 4:19 PM
Precipio, Inc.: Precipios Q4-2023 Cash Burn From Operations (unaudited) drops below $100K for the full quarterPrecipio, Inc.: Precipio's Q4-2023 Cash Burn From Operations (unaudited) drops below $100K for the full quarter
finanznachrichten.de - January 23 at 4:19 PM
Precipio’s Q4-2023 Cash Burn From Operations (unaudited) drops below $100K for the full quarterPrecipio’s Q4-2023 Cash Burn From Operations (unaudited) drops below $100K for the full quarter
finance.yahoo.com - January 23 at 4:19 PM
Precipio, Inc.: Precipio Signs Distribution Agreement For IV-Cell and HemeScreen in JapanPrecipio, Inc.: Precipio Signs Distribution Agreement For IV-Cell and HemeScreen in Japan
finanznachrichten.de - January 17 at 3:59 PM
Precipio Signs Distribution Agreement For IV-Cell® and HemeScreen® in JapanPrecipio Signs Distribution Agreement For IV-Cell® and HemeScreen® in Japan
finance.yahoo.com - January 17 at 3:59 PM
Precipio Announces Christina Valauri joins the Board of DirectorsPrecipio Announces Christina Valauri joins the Board of Directors
finance.yahoo.com - January 2 at 9:25 AM
Precipio, Inc.: Precipio Management Shares Thoughts on 2023, and Looks Ahead To 2024Precipio, Inc.: Precipio Management Shares Thoughts on 2023, and Looks Ahead To 2024
finanznachrichten.de - December 15 at 8:20 AM
Precipio Management Shares Thoughts on 2023, and Looks Ahead To 2024Precipio Management Shares Thoughts on 2023, and Looks Ahead To 2024
finance.yahoo.com - December 14 at 7:47 PM
Precipio: Regulation Fd Disclosure, Financial Statements And ExhibitsPrecipio: Regulation Fd Disclosure, Financial Statements And Exhibits
cbonds.com - November 18 at 7:00 AM
Precipio to Report $4.5M Q3-2023 Revenues, Double From Q3-2022Precipio to Report $4.5M Q3-2023 Revenues, Double From Q3-2022
finance.yahoo.com - October 18 at 9:36 AM
Precipio, Inc.: Precipios Q3 Cash Burn From Operations (unaudited) Declines 59% YoY, from $2.5M in Q3-2022 to approximately $1M in Q3-2023Precipio, Inc.: Precipio's Q3 Cash Burn From Operations (unaudited) Declines 59% YoY, from $2.5M in Q3-2022 to approximately $1M in Q3-2023
finanznachrichten.de - October 3 at 1:42 PM
Precipio’s Q3 Cash Burn From Operations (unaudited) Declines 59% YoY, from $2.5M in Q3-2022 to approximately $1M in Q3-2023Precipio’s Q3 Cash Burn From Operations (unaudited) Declines 59% YoY, from $2.5M in Q3-2022 to approximately $1M in Q3-2023
finance.yahoo.com - October 3 at 1:42 PM
Precipio Continues to Sign New HemeScreen™ CustomersPrecipio Continues to Sign New HemeScreen™ Customers
finance.yahoo.com - September 28 at 2:36 PM
Precipio Reduces Product Revenue Result Needed for Cash Flow BreakevenPrecipio Reduces Product Revenue Result Needed for Cash Flow Breakeven
finance.yahoo.com - September 25 at 3:15 PM
Precipio, Inc.: Precipio Takes Final Step Towards Regaining Nasdaq CompliancePrecipio, Inc.: Precipio Takes Final Step Towards Regaining Nasdaq Compliance
finanznachrichten.de - September 22 at 10:32 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Aethlon Medical logo

Aethlon Medical

NASDAQ:AEMD
Aethlon Medical, Inc., a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system. The company was founded in 1999 and is based in San Diego, California.
Arrayit logo

Arrayit

OTCMKTS:ARYC
Arrayit Corporation, a life sciences technology company, develops, manufactures, and markets life science tools and integrated systems for the analysis of genetic variation, biological function, and diagnostics worldwide. The company is involved in the development and support of microarray tools and components; custom printing and analysis of microarrays for research; and the identification and development of diagnostic microarrays and tools for early detection of treatable disease states. It offers microarray printing technology, which allows the manufacture of DNA, protein, antibody, lipid, carbohydrate, and other types of microarrays for research and diagnostic applications, including gene expression, genotyping, protein profiling, and others. The company also provides automated microarray manufacturing instruments, including NanoPrint, SpotBot Titan, SpotBot Extreme, SpotBo Protein, and Personal microarrayers, as well as SpotLight CCD fluorescence scanners, SpotWare colorimetric scanners, InnoScan laser scanners, TrayMix hybridization stations, ArrayMix hybridization stations, centrifuges, air jets, vacuum products, and laboratory tools and bioinformatics computers. In addition, it manufactures consumables, such as glass substrates and slides, reagents, solutions, kits, and clean room supplies; and provides variation identification platform technology that allows diagnostic tests to be performed by depositing approximately 100,000 patient samples onto a single microarray. Further, the company is involved in the import, export, manufacture, and distribution of wholesale industrial chemicals. Arrayit Corporation offers its tools and services to genomic research centers, pharmaceutical companies, academic institutions, clinical research organizations, government agencies, and biotechnology companies. The company is headquartered in Sunnyvale, California.
Bionano Genomics logo

Bionano Genomics

NASDAQ:BNGO
Bionano Genomics, Inc. provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA. The company also provides Saphyr and Bionano compute servers; and VIA software, which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; OGM-Dx HemeOne testing; OGM-Dx FSHD, a test for individuals suspected of having FSHD type 1; and OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV for comprehensive testing. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.
HTG Molecular Diagnostics logo

HTG Molecular Diagnostics

NASDAQ:HTGM
HTG Molecular Diagnostics, Inc. engages in the provision of molecular technology solutions that facilitates molecular profiling. It serves the biopharmaceutical companies, academic research centres, and molecular testing laboratories. Its proprietary HTG EdgeSeq technology automates complex, highly multiplexed molecular profiling from solid and liquid samples, even when limited in amount. The company was founded by Bruce E. Seligmann in October 1997 and is headquartered in Tucson, AZ.
Precipio logo

Precipio

NASDAQ:PRPO
Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; HemeScreen, a suite of robust genetic diagnostic panels; and COVID-19 antibody tests. It sells ICE- technology kits to bio-pharma customers. The company is based in New Haven, Connecticut.